This case involves warning lables that were affixed to a popular antipsychotic medicataion and its generic counterparts. The drug in question was used to treat schizophrenia, as well as a number of other psychiatric disorders, under an established brand name for several years. Eventually, it was discovered that using the drug for an extended period of time left patients with a greatly increased risk of tardive dyskinesia, a neurological disorder characterized by involinatry and repetitive movements. As a result, the medication recieved an additional warning lable indicating that the drug should not be used for an extended period of time. However, while the name brand version of the drug carried the new warning label, the leading generic version of the medication did not. As a result, several individuals contracted tardive dyskinesia after taking the generic version of the drug for an extended period of time. It was alleged that the manufacturer of the generic drug failed to warn patients of the risks of long-term use.